Sun Pharma reports positive results for MM-II injection in knee osteoarthritis trial
Sun Pharma and Moebius Medical Limited, an Israel-based company, showcased compelling data at the European League Against Rheumatism (EULAR) 2024 conference. The results demonstrated the prolonged efficacy of the MM-II injection in providing pain relief for knee osteoarthritis (OA) patients up to 26 weeks post-injection. This data was derived from a phase 2b randomized controlled […]